24 hour – Page 14 – Communicable Diseases Research

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

Letter

Published on 2020-09-172022-10-29
Journal: Trials [Category] Coronavirus, SARS,

Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter

Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region

Research Article

Published on 2020-09-092022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] 24 hour 95% CI adjusted hazard ratio Admission age AHRF Care Cohort component Corticosteroid COVID-19 death Direct discharge evaluate the effect Final Follow-up for inclusion hospital Hospitalized hypoxemic hypoxic ICU In-hospital death in-hospital mortality intubation laboratory-confirmed men New York non-ICU non-ICU patient objective outcome outcomes PaO Patient patients patients with COVID-19 Pneumonia Primary outcome Respiratory failure Result retrospective cohort study risk screened secondary significantly lower single-center systemic corticosteroid therapeutic transfer treated Treatment were excluded with COVID-19
[DOI] 10.1371/journal.pone.0238827 PMC 바로가기 [Article Type] Research Article

How to perform and interpret the lung ultrasound by the obstetricians in pregnant women during the SARS-CoV-2 pandemic

Clinical Investigation

Published on 2020-09-022022-10-28
Journal: Turkish Journal of Obstetrics and Gynecology [Category] COVID-19,

[키워드] 24 hour Admission anatomical contribute Coronavirus 2019 Coronavirus-2 Course COVID-19 described diagnosed feasible indicated Interpretation limitation lung Lung ultrasound material pandemic pathologic Patient Pneumonia Pregnancy pregnant women provided respiratory Safe SARS-CoV-2 syndrome the SARS-CoV-2 was performed
[DOI] 10.4274/tjod.galenos.2020.93902 PMC 바로가기 [Article Type] Clinical Investigation

24 Hours: A Case of Multiorgan Failure Associated With COVID-19

Internal Medicine

Published on 2020-08-312022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] 24 hour acidosis Acute kidney injury acute respiratory distress Admission AKI ARDS caused COVID-19 Cytokine storm death died failure female Hemodialysis Hospital admission Injury less mechanism Mortality MOST progression renal renal failure Risk factors severe metabolic syndrome the disease the patient
[DOI] 10.7759/cureus.10149 PMC 바로가기 [Article Type] Internal Medicine

Neonates With Complex Cardiac Malformation and Congenital Diaphragmatic Hernia Born to SARS-CoV-2 Positive Women—A Single Center Experience

Original Articles

Published on 2020-08-272022-10-28
Journal: World Journal for Pediatric & Congenital Heart Sur [Category] COVID-19, MERS, SARS,

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-08-172022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] 24 hour absolute reduction Administered administration AIFA airway allocation sequence Alpha Anticoagulant anticoagulant therapy Anticoagulant treatment approval Arm Aspergillus assigned assumption average bleeding bleeding event blinded Block randomisation block size BMI Brain Breastfeeding Candida checked childbearing age chronic clinical clinical condition clinically combined use conjunctival contributed corpus Corticosteroid COVID-19 criteria Critical Critically ill cytomegalovirus D-dimer level death defined Delay detect diagnostic discharge dissemination dosage drug dysfunction effective element eligible patient enoxaparin enrolled EudraCT exclusion criteria expected hematemesis hematoma heparin-induced thrombocytopenia Herpe high risk High-dose history hospital hospital discharge Hypothesis ICU ICU free day ICU Patients impairing Inclusion inclusion criteria indicated Infection initial Inpatient intensive care unit interval Intervention Intra-articular intramuscular intravenously invasive Invasive mechanical ventilation investigator Italian limit LMWH low molecular weight low-molecular weight heparin macroscopic major bleeding mechanical ventilation medical intervention Methylprednisolone Mortality mortality rate Myocardial Non-invasive non-invasive ventilation number objective occur ophthalmic organ dysfunction PaO parallel group participant Patient performed Pharyngeal swab Pneumonia positive positive pressure pregnancy test Presence Prophylactic prophylactic dose Prophylaxis protocol random randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly Ratio receive recent recruited recruitment Rectal Bleeding red blood cell reduce reducing Registered required risk of death Safety Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia secondary secure severe disease sick significantly sodium status steroid stratified stroke study drug Study protocol subcutaneously surgical syndrome therapeutic therapeutic doses therapy Treatment treatment group unfractionated heparin Venous Thromboembolism ventilated patient Ventilation website Weighting Withdrawal women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter

Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells

Research Article

Published on 2020-07-312022-10-31
Journal: Emerging Microbes & Infections [Category] COVID-19, MERS, SARS,

[키워드] 24 hour acute respiratory syndrome Akt/mTOR/HIF-1 Analysis cellular cellular response Coronavirus-2 Course COVID-19 dose-dependent activation downstream effector molecule engage ErbB HIF-1 HIF-1α Host hpi Huh7 cell in vitro infected cell Infection inhibition inhibitor Innate immunity management MK-2206 modulated molecular mTOR signaling pathway Pathways patients performed post infection potential therapy proteomics reduction in required S6K1 SARS-CoV-2 SARS-CoV-2 infected cell severe coronavirus disease Signaling signaling pathways the SARS-CoV-2 TNF signaling transcriptomics virus virus production
[DOI] 10.1080/22221751.2020.1799723 PMC 바로가기 [Article Type] Research Article

PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial

Study Protocol

Published on 2020-07-312022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 24 hour addition Administered adverse event all subject allocation sequence Analysis antiviral activity Antiviral effect Arm arrhythmia Asymptomatic bradycardia can be used carried Cell Chronic kidney disease clinical Cluster Clusters Comorbidity Compliance conducted congestive heart failure Contact contraindication Coronaviruses covariates COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient COVID-19 patients COVID-19 symptom Data monitoring committee database deficiency defined Department diabete diagnostic dialysis disease dissemination diuretics dose drug Drug-drug interactions during treatment early treatment Efficacy element eligible endosomal pH ENhance enrolled Epidemic Epidemiology equation EudraCT evaluate Evidence expected Factor female Final G6PD Generalized generate Glucose-6-phosphate glycosylation group Healthcare professional Hydroxychloroquine hydroxychloroquine/chloroquine identify in vitro in vivo inclusion criteria independent index index case index cases Infection interim analysis involved IRCCS ischemic heart disease Italian region Italy Loading dose male malignancy medication mental illness mild symptoms neurological number objective observation open label oropharyngeal swab outcome parallel group participant Patient patients with COVID-19 Paucisymptomatic performed positive PCR test Prevent prevention prevention of COVID-19 Prophylaxis proportion Proteins protocol protocol amendment Public QT prolongation randomization Randomized Randomized controlled clinical trial Randomized controlled trial reached receive recorded recruited reduced reduction in Registered reported required risk Sample size SARS-CoV-2 shown Standard status stratified Studio Study protocol subject subjects Support Swab Symptom symptomatic syndrome Tablet therapeutic approaches therapy Toxicity treat treated Treatment Trial trial protocol ventricular viral surface virus virus infection website with COVID-19
[DOI] 10.1186/s13063-020-04527-4 PMC 바로가기 [Article Type] Study Protocol

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-132022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter